The role of antimicrobial peptides in preventing multidrug-resistant bacterial infections and biofilm formation

International Journal of Molecular Sciences

Volumn 12, Issue 9, 2011, Pages 5971-5992

  Park, Seong Cheol ^a   Park, Yoonkyung ^a   Hahm, Kyung Soo ^a,b  

^a Chosun University   (South Korea)

^b Bioleaders Corporation   (South Korea)

Author keywords

Dental plaque; Lipopolysaccharide; Mode of action; Quorum sensing; Synergetic effect

Indexed keywords

ANTIBIOTIC AGENT; BACTERIUM LIPOPOLYSACCHARIDE; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CECROPIN A; CITROPIN 1.1; COLISTIN; IB 367; IMIPENEM; INDOLICIDIN; ISEGANAN; LACTOFERRIN; LANTIBIOTIC; MAGAININ 2; MERSACIDIN; MINOCYCLINE; MX 226; NISIN; OMEGANAN; OPEBACAN; PEPTIDOGLYCAN; PEXIGANAN; PLECTASIN; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT; PORCINE MYELOID ANTIBACTERIAL PEPTIDE 23; RIFAMPICIN; SUBTILIN; SUSHI PEPTIDE; TACHYPLESIN; TACHYPLESIN 3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; ANTIMICROBIAL CATIONIC PEPTIDE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL CELL WALL; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BIOFILM; BLOODSTREAM INFECTION; CATHETER INFECTION; CELL DIVISION; CELL INTERACTION; CELL MEMBRANE PERMEABILITY; CELL MEMBRANE POTENTIAL; COMBINATION CHEMOTHERAPY; DIABETIC FOOT; DRUG ABSORPTION; DRUG DNA BINDING; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; ENDOTOXEMIA; HUMAN; IN VIVO STUDY; INFECTION PREVENTION; LIPID MEMBRANE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MOUTH PLAQUE; MUCOSA INFLAMMATION; MULTIDRUG RESISTANCE; NONHUMAN; PROCESS MODEL; PSEUDOMONAS INFECTION; REVIEW; SEPSIS; SEPTIC SHOCK; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; BACTERIA; BACTERIAL INFECTIONS; BACTERIAL PHENOMENA AND FUNCTIONS; BIOLOGICAL MODEL; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

BACTERIA (MICROORGANISMS);

ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIA; BACTERIAL INFECTIONS; BACTERIAL PHYSIOLOGICAL PHENOMENA; BIOFILMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL;

EID: 80053184140     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms12095971     Document Type: Review

References (179)

1. Klein, E.; Smith, D.L.; Laxminarayan, R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg. Infect. Dis. 2007, 13, 1840-1846.
2. Klevens, R.M.; Edwards, J.R.; Richards, C.L.; Jr Horan, T.C.; Gaynes, R.P.; Pollock, D.A.; Cardo, D.M. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep. 2007, 122, 160-166.
3. Johnson, A.P.; Pearson, A.; Duckworth, G. Surveillance and epidemiology of MRSA bacteraemia in the UK. J. Antimicrob. Chemother. 2005, 56, 455-462.
4. Monroe, D. Looking for chinks in the armor of bacterial biofilms. PLoS Biol. 2007, 5, e307.
5. Hall-Stoodley, L.; Costerton, J.W.; Stoodley, P. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2004, 2, 95-108.
6. Stewart, P.S.; Costerton, J.W. Antibiotic resistance of bacteria in biofilms. Lancet 2001, 358, 135-138.
7. Stamm, W.E. Catheter-associated urinary tract infections: Epidemiology, pathogenesis, and prevention. Am. J. Med. 1991, 91, 65S-71S.
8. Nickel, J.C.; Costerton, J.W.; McLean, R.J.; Olson, M. Bacterial biofilms: influence on the pathogenesis, diagnosis and treatment of urinary tract infections. J. Antimicrob. Chemother. 1994, 33, 31-41.
9. Hojo, K.; Nagaoka, S.; Ohshima, T.; Maeda, N. Bacterial interactions in dental biofilm development. J. Dent. Res. 2009, 88, 982-990.
10. O'Grady, N.P.; Aexander, M.; Dellinger, E.P.; Gerberding, J.L.; Heard, S.O.; Maki, D.G.; Masur, H.; McCormick, R.D.; Mermel, L.A.; Pearson, M.L.; et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for disease control and prevention. MMWR Recomm. Rep. 2002, 51, 1-29.
11. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415, 389-395.
12. Chan, D.I.; Prenner, E.J.; Vogel, H.J. Tryptophan-and arginine-rich antimicrobial peptides: structures and mechanisms of action. Biochim. Biophys. Acta 2006, 1758, 1184-1202.
13. Oppenheim, J.J.; Biragyn, A.; Kwak, L.W.; Yang, D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann. Rheum. Dis. 2003, 62, 2 17-21.
14. Steiner, H.; Hultmark, D.; Engström, A.; Bennich, H.; Boman, H.G. Sequence and specificity of two antibacterial proteins involved in insect immunity. Nature 1981, 292, 246-248.
15. Gibson, B.W.; Poulter, L.; Williams, D.H. A mass spectrometric assay for novel peptides: Application to Xenopus laevis skin secretions. Peptides 1985, 6, 23-27.
16. Zasloff, M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc. Natl. Acad. Sci. USA 1987, 84, 5449-5453.
17. Yeaman, M.R.; Yount, N.Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 2003, 55, 27-55.
18. Brogden, K.A. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 2005, 3, 238-250.
19. Pieters, R.J.; Arnusch, C.J.; Breukink, E. Membrane permeabilization by multivalent anti-microbial peptides. Protein Pept. Lett. 2009, 16, 736-742.
20. Nicias, P. Multifunctional host defense peptides: Intracellular-targeting antimicrobial peptides. FEBS J. 2009, 276, 6483-6496.
21. Friedrich, C.; Scott, M.G.; Karunaratne, N.; Yan, H.; Hancock, R.E. Salt-resistant alpha-helical cationic antimicrobial peptides. Antimicrob. Agents Chemother. 1999, 43, 1542-1548.
22. Mukhopadhyay, K.; Whitmire, W.; Xiong, Y.Q.; Molden, J.; Jones, T.; Peschel, A.; Staubitz, P.; Adler-Moore, J.; McNamara, P.J.; Proctor, R.A.; Yeaman, M.R.; Bayer, A.S. In vitro susceptibility of Staphylococcus aureus to thrombin-induced platelet microbicidal protein-1 (tPMP-1) is influenced by cell membrane phospholipid composition and asymmetry. Microbiology 2007, 153, 1187-1197.
23. Thwaite, J.E.; Hibbs, S.; Titball, R.W.; Atkins, T.P. Proteolytic degradation of human antimicrobial peptide LL-37 by Bacillus anthracis may contribute to virulence. Antimicrob. Agents Chemother. 2006, 50, 2316-2322.
24. McGillivray, S.M.; Ebrahimi, C.M.; Fisher, N.; Sabet, M.; Zhang, D.X.; Chen, Y.; Haste, N.M.; Aroian, R.V.; Gallo, R.L.; Guiney, D.G.; Friedlander, A.M.; Koehler, T.M.; Nizet, V. Clp X Contributes to innate defense peptide resistance and virulence phenotypes of Bacillus anthracis. J. Innate Immun. 2009, 1, 494-506.
25. Giacometti, A.; Cirioni, O.; Kamysz, W.; D'Amato, G.; Silvestri, C.; Simona Del Prete, M.; Lukasiak, J.; Scalise, G. In vitro activity and killing effect of the synthetic hybrid cecropin A-melittin peptide CA(1-7)M(2-9)NH(2) on methicillin-resistant nosocomial isolates of Staphylococcus aureus and interactions with clinically used antibiotics. Diagn. Microbiol. Infect. Dis. 2004, 49, 197-200.
26. Park, Y.; Park, S.N.; Park, S.C.; Shin, S.O.; Kim, J.Y.; Kang, S.J.; Kim, M.H.; Jeong, C.Y.; Hahm, K.S. Synergism of Leu-Lys rich antimicrobial peptides and chloramphenicol against bacterial cells. Biochim. Biophys. Acta 2006, 1764, 24-32.
27. Park, Y.; Kim, H.J.; Hahm, K.S. Antibacterial synergism of novel antibiotic peptides with chloramphenicol. Biochem. Biophys. Res. Commun. 2004, 321, 109-115.
28. Gutsmann, T.; Hagge, S.O.; David, A.; Roes, S.; Böhling, A.; Hammer, M.U.; Seydel, U. Lipid-mediated resistance of Gram-negative bacteria against various pore-forming antimicrobial peptides. J. Endotoxin Res. 2005, 11, 167-173.
29. Gee, K.; Kozlowski, M.; Kumar, A. Tumor necrosis factor-alpha induces functionally active hyaluronan-adhesive CD44 by activating sialidase through p38 mitogen-activated protein kinase in lipopolysaccharide-stimulated human monocytic cells. J. Biol. Chem. 2003, 278, 37275-37287.
30. Blanqué, R.; Meakin, C.; Millet, S.; Gardner, C.R. Hypothermia as an indicator of the acute effects of lipopolysaccharides: Comparison with serum levels of IL1 beta, IL6 and TNF alpha. Gen. Pharmacol. 1996, 27, 973-977.
31. Freudenberg, M.A.; Tchaptchet, S.; Keck, S.; Fejer, G.; Huber, M.; Schütze, N.; Beutler, B.; Galanos, C. Lipopolysaccharide sensing an important factor in the innate immune response to Gram-negative bacterial infections: Benefits and hazards of LPS hypersensitivity. Immunobiology 2008, 213, 193-203.
32. Li, P.; Wohland, T.; Ho, B.; Ding, J.L. Perturbation of Lipopolysaccharide (LPS) Micelles by Sushi 3 (S3) antimicrobial peptide. The importance of an intermolecular disulfide bond in S3 dimer for binding, disruption, and neutralization of LPS. J. Biol. Chem. 2004, 279, 50150-50156.
33. Bhattacharjya, S.; Domadia, P.N.; Bhunia, A.; Malladi, S.; David, S.A. High-resolution solution structure of a designed peptide bound to lipopolysaccharide: transferred nuclear overhauser effects, micelle selectivity, and anti-endotoxic activity. Biochemistry 2007, 46, 5864-5874.
34. Storm, D.R.; Rosental, K.S.; Swanson, P.E. Polymyxin and related peptide antibiotics. Annu. Rev. Biochem. 1977, 46, 723-763.
35. Kwa, A.; Kasiakou, S.K.; Tam, V.H.; Falagas, M.E. Polymyxin B: Similarities to and differences from colistin (polymyxin E). Expert Rev. Anti-Infect. Ther. 2007, 5, 811-821.
36. Mogi, T.; Kita, K. Gramicidin S and polymyxins: The revival of cationic cyclic peptide antibiotics. Cell. Mol. Life Sci. 2007, 66, 3821-3826.
37. Ding, J.L.; Li, P.; Ho, B. The Sushi peptides: structural characterization and mode of action against Gram-negative bacteria. Cell. Mol. Life Sci.2008, 65, 1202-1219.
38. Kim, J.Y.; Park, S.C.; Yoon, M.Y.; Hahm, K.S.; Park, Y. C-terminal amidation of PMAP-23: Translocation to the inner membrane of Gram-negative bacteria. Amino Acids 2011, 40, 183-195.
39. Gough, M.; Hancock, R.E.; Kelly, N.M. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect. Immun. 1996, 64, 4922-4927.
40. Scott, M.G.; Yan, H.; Hancock, R.E. Biological properties of structurally related alpha-helical cationic antimicrobial peptides. Infect. Immun. 1999, 67, 2005-2009.
41. Giacometti, A.; Cirioni, O.; Ghiselli, R.; Mocchegiani, F.; Del Prete, M.S.; Viticchi, C.; Kamysz, W.; Lempicka, E.; Saba, V.; Scalise, G. Potential therapeutic role of cationic peptides in three experimental models of septic shock. Antimicrob. Agents Chemother. 2002, 46, 2132-2136.
42. Guo, L.; Lim, K.B.; Poduje, C.M.; Daniel, M.; Gunn, J.S.; Hackett, M.; Miller, S.I. Lipid A acylation and bacterial resistance against vertebrate antimicrobial peptides. Cell 1998, 95, 189-198.
43. Zhou, Z.; Lin, S.; Cotter, R.J.; Raetz, C.R. Lipid A modifications characteristic of Salmonella typhimurium are induced by NH4VO3 in Escherichia coli K12. Detection of 4-amino-4-deoxy-L-arabinose, phosphoethanolamine and palmitate. J. Biol. Chem. 1999, 274, 18503-18514.
44. Ernst, R.K.; Guina, T.; Miller, S.I. How intracellular bacteria survive: surface modifications that promote resistance to host innate immune responses. J. Infect. Dis. 1999, 179, S326-S330.
45. Glaser, L. Bacterial cell surface polysaccharides. Annu. Rev. Biochem. 1973, 42, 91-112.
46. Di Guilmi, A.M.; Dessen, A.; Dideberg, O.; Vernet, T. Bifunctional penicillin-binding proteins: Focus on the glycosyltransferase domain and its specific inhibitor moenomycin. Curr. Pharm. Biotechnol. 2002, 3, 63-75.
47. Wilke, M.S.; Lovering, A.L.; Strynadka, N.C. Beta-lactam antibiotic resistance: a current structural perspective. Curr. Opin. Microbiol. 2005, 8, 525-533.
48. Brakstad, O.G.; Maeland, J.A. Mechanisms of methicillin resistance in staphylococci. APMIS 1997, 105, 264-276.
49. Berger-Bächi, B.; Rohrer, S. Factors influencing methicillin resistance in staphylococci. Arch. Microbiol. 2002, 178, 165-171.
50. Gin, A.S.; Zhanel, G.G. Vancomycin-resistant enterococci. Ann. Pharmacother. 1996, 30, 615-624.
51. Bierbaum, G.; Sahl, H.G. Lantibiotics: Mode of action, biosynthesis and bioengineering. Curr. Pharm. Biotechnol. 2009, 10, 2-18.
52. Mattick, A.T.; Hirsch, A. Further observations on an inhibitory substance (nisin) from lactic streptococci. Lancet 1947, 2, 5-8.
53. Jansen, E.F.; Hirschmann, D.J. Binding of simple carbohydrates and some N-acetyllactosaminecontaining oligosaccharides to Erythrina cristagalli agglutinin as followed with a fluorescent indicator ligand. Arch. Biochem. 1994, 4, 297-304.
54. Allgaier, H.; Jung, G.; Werner, R.G.; Schneider, U.; Zähner, H. Epidermin: sequencing of a heterodetic tetracyclic 21-peptide amide antibiotic. Eur. J. Biochem. 1986, 160, 9-22.
55. Sahl, H.G.; Grossgarten, M.; Widger, W.R.; Cramer, W.A.; Brandis, H. Structural similarities of the staphylococcin-like peptide Pep-5 to the peptide antibiotic nisin. Antimicrob. Agents Chemother. 1985, 27, 836-840.
56. Chatterjee, S.; Chatterjee, S.; Lad, S.J.; Phansalkar, M.S.; Rupp, R.H.; Ganguli, B.N.; Fehlhaber, H.W.; Kogler, H. Mersacidin, a new antibiotic from Bacillus. Fermentation, isolation, purification and chemical characterization. J. Antibiot. 1992, 45, 832-838.
57. Fredenhagen, A.; Fendrich, G.; Märki, F.; Märki, W.; Gruner, J.; Raschdorf, F.; Peter, H.H. Duramycins B and C, two new lanthionine containing antibiotics as inhibitors of phospholipase A2. Structural revision of duramycin and cinnamycin. J. Antibiot. 1990, 43, 1403-1412.
58. Hansen, J.N. Nisin as a model food preservative. Crit. Rev. Food Sci. Nutr. 1994, 34, 69-93.
59. Hasper, H.E.; Kramer, N.E.; Smith, J.L.; Hillman, J.D.; Zachariah, C.; Kuipers, O.P.; de Kruijff, B.; Breukink, E. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. Science 2006, 313, 1636-1637.
60. Bierbaum, G.; Sahl, H.G. Lantibiotics: Mode of action, biosynthesis and bioengineering. Curr. Pharm. Biotechnol. 2009, 10, 2-18.
61. Hsu, S.T.; Breukink, E.; Tischenko, E.; Lutters, M.A.; de Kruijff, B.; Kaptein, R.; Bonvin, A.M.; van Nuland, N.A. The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat. Struct. Mol. Biol. 2004, 11, 963-967.
62. Parisot, J.; Carey, S.; Breukink, E.; Chan, W.C.; Narbad, A.; Bonev, B. Molecular mechanism of target recognition by subtilin, a class I lanthionine antibiotic. Antimicrob. Agents Chemother. 2008, 52, 612-618.
63. Sahl, H.G.; Jack, R.W.; Bierbaum, G. Biosynthesis and biological activities of lantibiotics with unique post-translational modifications. Eur. J. Biochem. 1995, 230, 827-853.
64. Brötz, H.; Bierbaum, G.; Leopold, K.; Reynolds, P.E.; Sahl, H.G. The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrob. Agents Chemother. 1998, 42, 154-160.
65. Alibert-Franco, S.; Pradines, B.; Mahamoud, A.; Davin-Regli, A.; Pagès, J.M. Efflux mechanism, an attractive target to combat multidrug resistant Plasmodium falciparum and Pseudomonas aeruginosa. Curr. Med. Chem. 2009, 16, 301-317.
66. Langton, K.P.; Henderson, P.J.; Herbert, R.B. Antibiotic resistance: Multidrug efflux proteins, a common transport mechanism? Nat. Prod. Rep. 2005, 22, 439-451.
67. Zgurskaya, H.I.; Krishnamoorthy, G.; Tikhonova, E.B.; Lau, S.Y.; Stratton, K.L. Mechanism of antibiotic efflux in Gram-negative bacteria. Front Biosci. 2003, 8, s862-s873.
68. Pérez, A.; Canle, D.; Latasa, C.; Poza, M.; Beceiro, A.; Tomás Mdel, M.; Fernández, A.; Mallo, S.; Pérez, S.; Molina, F.; et al. Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. Antimicrob. Agents Chemother. 2007, 51, 3247-3253.
69. Nicolas, P. Multifunctional host defense peptides: Intracellular-targeting antimicrobial peptides. FEBS J. 2009, 276, 6483-6496.
70. Oren, Z.; Shai, Y. Mode of action of linear amphipathic alpha-helical antimicrobial peptides. Biopolymers 1998, 47, 451-463.
71. Mihajlovic, M.; Lazaridis, T. Antimicrobial peptides in toroidal and cylindrical pores. Biochim. Biophys. Acta 2010, 1798, 1485-1493.
72. Gottler, L.M.; Ramamoorthy, A. Structure, membrane orientation, mechanism, and function of pexiganan-a highly potent antimicrobial peptide designed from magainin. Biochim. Biophys. Acta 2009, 1788, 1680-1686.
73. Shai, Y.; Oren, Z. From "carpet" mechanism to de-novo designed diastereomeric cell-selective antimicrobial peptides. Peptides 2001, 22, 1629-1641.
74. Ramamoorthy, A.; Lee, D.K.; Narasimhaswamy, T.; Nanga, R.P. Cholesterol reduces pardaxin's dynamics-a barrel-stave mechanism of membrane disruption investigated by solid-state NMR. Biochim. Biophys. Acta. 2010, 1798, 223-227.
75. Cantor, R.S. Size distribution of barrel-stave aggregates of membrane peptides: Influence of the bilayer lateral pressure profile. Biophys. J. 2002, 82, 2520-2525.
76. Bessin, Y.; Saint, N.; Marri, L.; Marchini, D.; Molle, G. Antibacterial activity and pore-forming properties of ceratotoxins: A mechanism of action based on the barrel stave model. Biochim. Biophys. Acta 2004, 1667, 148-156.
77. Gazit, E.; Miller, I.R.; Biggin, P.C.; Sansom, M.S.; Shai, Y. Structure and orientation of the mammalian antibacterial peptide cecropin P1 within phospholipid membranes. J. Mol. Biol. 1996, 258, 860-870.
78. Wong, H.; Bowie, J.H.; Carver, J.A. The solution structure and activity of caerin 1.1, an antimicrobial peptide from the Australian green tree frog, Litoria splendida. Eur. J. Biochem. 1997, 247, 545-557.
79. Ludtke, S.J.; He, K.; Heller, W.T.; Harroun, T.A.; Yang, L.; Huang, H.W. Membrane pores induced by magainin. Biochemistry 1996, 35, 13723-13728.
80. Tamba, Y.; Yamazaki, M. Magainin 2-induced pore formation in the lipid membranes depends on its concentration in the membrane interface. J. Phys. Chem. B 2009, 113, 4846-4852.
81. Basanez, G.; Shinnar, A.E.; Zimmerberg, J. Interaction of hagfish cathelicidin antimicrobial peptides with model lipid membranes. FEBS Lett. 2002, 532, 115-120.
82. Henzler Wildman, K.A.; Lee, D.K.; Ramamoorthy, A. Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry 2003, 42, 6545-6558.
83. Park, S.C.; Kim, M.H.; Hossain, M.A.; Shin, S.Y.; Kim, Y.; Stella, L.; Wade, J.D.; Park, Y.; Hahm, K.S. Amphipathic alpha-helical peptide, HP (2-20), and its analogues derived from Helicobacter pylori: Pore formation mechanism in various lipid compositions. Biochim. Biophys. Acta 2008, 1778, 229-241.
84. Lee, T.H.; Hall, K.N.; Swann, M.J.; Popplewell, J.F.; Unabia, S.; Park, Y.; Hahm, K.S.; Aguilar, M.I. The membrane insertion of helical antimicrobial peptides from the N-terminus of Helicobacter pylori ribosomal protein L1. Biochim. Biophys. Acta 2010, 1798, 544-557.
85. Park, S.C.; Kim, J.Y.; Shin, S.O.; Jeong, C.Y.; Kim, M.H.; Shin, S.Y.; Cheong, G.W.; Park, Y.; Hahm, K.S. Investigation of toroidal pore and oligomerization by melittin using transmission electron microscopy. Biochem. Biophys. Res. Commun. 2006, 343, 222-228.
86. Han, M.; Mei, Y.; Khant, H.; Ludtke, S.J. Characterization of antibiotic peptide pores using cryo-EM and comparison to neutron scattering. Biophys. J. 2009, 97, 164-172.
87. Yang, L.; Harroun, T.A.; Weiss, T.M.; Ding, L.; Huang, H.W. Barrel-stave model or toroidal model? A case study on melittin pores. Biophys. J. 2001, 81, 1475-1485.
88. Allende, D.; Simon, S.A.; McIntosh, T.J. Melittin-induced bilayer leakage depends on lipid material properties: evidence for toroidal pores. Biophys. J. 2005, 88, 1828-1837.
89. Kragol, G.; Hoffmann, R.; Chattergoon, M.A.; Lovas, S.; Cudic, M.; Bulet, P.; Condie, B.A.; Rosengren, K.J.; Montaner, L.J.; Otvos, L., Jr. Identification of crucial residues for the antibacterial activity of the proline-rich peptide, pyrrhocoricin. Eur. J. Biochem. 2002, 269, 4226-4237.
90. Kragol, G.; Lovas, S.; Varadi, G.; Condie, B.A.; Hoffmann, R.; Otvos, L., Jr. The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry 2001, 40, 3016-3026.
91. Otvos, L., Jr.; Insug, O.; Rogers, M.E.; Consolvo, P.J.; Condie, B.A.; Lovas, S.; Bulet, P.; Blaszczyk-Thurin, M. Interaction between heat shock proteins and antimicrobial peptides. Biochemistry 2000, 39, 14150-14159.
92. Vizan, J.L.; Hernández-Chico, C.; del Castillo, I.; Moreno, F. The peptide antibiotic microcin B17 induces double-strand cleavage of DNA mediated by E. coli DNA gyrase. EMBO J. 1991, 10, 467-476.
93. Park, C.B.; Kim, H.S.; Kim, S.C. Mechanism of action of the antimicrobial peptide buforin II: Buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem. Biophys. Res. Commun. 1998, 244, 253-257.
94. Boman, H.G.; Agerberth, B.; Boman, A. Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine. Infect. Immun.1993, 61, 2978-2984.
95. Subbalakshmi, C.; Sitaram, N. Mechanism of antimicrobial action of indolicidin. FEMS Microbiol. Lett. 1998, 160, 91-96.
96. Xiong, Y.Q.; Bayer, A.S.; Yeaman, M.R. Inhibition of intracellular macromolecular synthesis in Staphylococcus aureus by thrombin-induced platelet microbicidal proteins. J. Infect. Dis. 2002, 185, 348-356.
97. Cho, J.H.; Sung, B.H.; Kim, S.C. Buforins: histone H2A-derived antimicrobial peptides from toad stomach. Biochim. Biophys. Acta 2009, 1788, 1564-1569.
98. Hsu, C.H.; Chen, C.; Jou, M.L.; Lee, A.Y.; Lin, Y.C.; Yu, Y.P.; Huang, W.T.; Wu, S.H. Structural and DNA-binding studies on the bovine antimicrobial peptide, indolicidin: Evidence for multiple conformations involved in binding to membranes and DNA. Nucleic Acids Res. 2005, 33, 4053-4064
99. Barriere, S.L. Bacterial resistance to beta-lactams, and its prevention with combination antimicrobial therapy. Pharmacotherapy 1992, 12, 397-402.
100. Wu, Y.L.; Scott, E.M.; Po, A.L.; Tariq, V.N. Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 1999, 44, 389-392.
101. Steenbergen, J.N.; Mohr, J.F.; Thorne, G.M. Effects of daptomycin in combination with other antimicrobial agents: A review of in vitro and animal model studies. J. Antimicrob. Chemother. 2009, 64, 1130-1138.
102. Anantharaman, A.; Rizvi, M.S.; Sahal, D. Synergy with rifampin and kanamycin enhances potency, kill kinetics, and selectivity of de novo-designed antimicrobial peptides. Antimicrob. Agents Chemother. 2010, 54, 1693-1699.
103. Cirioni, O.; Silvestri, C.; Ghiselli, R.; Orlando, F.; Riva, A.; Mocchegiani, F.; Chiodi, L.; Castelletti, S.; Gabrielli, E.; Saba, V.; et al. Protective effects of the combination of alpha-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection. J. Antimicrob. Chemother. 2008, 62, 1332-1338.
104. Cirioni, O.; Ghiselli, R.; Silvestri, C.; Kamysz, W.; Orlando, F.; Mocchegiani, F.; Di Matteo, F.; Riva, A.; Lukasiak, J.; Scalise, G.; et al. Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain. Antimicrob. Agents Chemother. 2007, 51, 2005-2010.
105. Jeong, N.; Kim, J.Y.; Park, S.C.; Lee, J.K.; Gopal, R.; Yoo, S.; Son, B.K.; Hahm, J.S.; Park, Y.; Hahm, K.S. Antibiotic and synergistic effect of Leu-Lys rich peptide against antibiotic resistant microorganisms isolated from patients with cholelithiasis. Biochem. Biophys. Res. Commun. 2010, 399, 581-586.
106. McGregor, D.P. Discovering and improving novel peptide therapeutics. Curr. Opin. Pharmacol. 2008, 8, 616-619.
107. Svenson, J.; Stensen, W.; Brandsdal, B.O.; Haug, B.E.; Monrad, J.; Svendsen, J.S. Antimicrobial peptides with stability toward tryptic degradation. Biochemistry 2008, 47, 3777-3788.
108. Park, K.H.; Nan, Y.H.; Park, Y.; Kim, J.I.; Park, I.S.; Hahm, K.S.; Shin, S.Y. Cell specificity, anti-inflammatory activity, and plausible bactericidal mechanism of designed Trp-rich model antimicrobial peptides. Biochim. Biophys. Acta 2009, 1788, 1193-1203.
109. Whitcomb, D.C.; Lowe, M.E. Human pancreatic digestive enzymes. Dig. Dis. Sci. 2007, 52, 1-17.
110. Gray, G.M.; Cooper, H.L. Protein digestion and absorption. Gastroenterology 1971, 61, 535-544.
111. Park, Y.; Park, S.C.; Kim, J.Y.; Park, J.O.; Seo, C.H.; Nah, J.W.; Hahm, K.S. In vitro efficacy of a synthetic all-d antimicrobial peptide against clinically isolated drug-resistant strains. Int. J. Antimicrob. Agents 2010, 35, 208-209.
112. Wang, P.; Nan, Y.H.; Yang, S.T.; Kang, S.W.; Kim, Y.; Park, I.S.; Hahm, K.S.; Shin, S.Y. Cell selectivity and anti-inflammatory activity of a Leu/Lys-rich alpha-helical model antimicrobial peptide and its diastereomeric peptides. Peptides 2010, 31, 1251-1261.
113. Dartois, V.; Sanchez-Quesada, J.; Cabezas, E.; Chi, E.; Dubbelde, C.; Dunn, C.; Granja, J.; Gritzen, C.; Weinberger, D.; Ghadiri, M.R.; et al. Systemic antibacterial activity of novel synthetic cyclic peptides. Antimicrob. Agents Chemother. 2005, 49, 3302-3310.
114. Rozek, A.; Powers, J.P.; Friedrich, C.L.; Hancock, R.E. Structure-based design of an indolicidin peptide analogue with increased protease stability. Biochemistry 2003, 42, 14130-14138.
115. Avrahami, D.; Shai, Y. Conjugation of a magainin analogue with lipophilic acids controls hydrophobicity, solution assembly, and cell selectivity. Biochemistry 2002, 41, 2254-2263.
116. Chongsiriwatana, N.P.; Patch, J.A.; Czyzewski, A.M.; Dohm, M.T.; Ivankin, A.; Gidalevitz, D.; Zuckermann, R.N.; Barron, A.E. Peptoids that mimic the structure, function, and mechanism of helical antimicrobial peptides. Proc. Natl. Acad. Sci. USA 2008, 105, 2794-2799.
117. Wang, P.; Bang, J.K.; Kim, H.J.; Kim, J.K.; Kim, Y.; Shin, S.Y. Antimicrobial specificity and mechanism of action of disulfide-removed linear analogs of the plant-derived Cys-rich antimicrobial peptide Ib-AMP1. Peptides 2009, 30, 2144-2149.
118. Meng, H.; Kumar, K. Antimicrobial activity and protease stability of peptides containing fluorinated amino acids. J. Am. Chem. Soc. 2007, 129, 15615-15622.
119. Porter, E.A.; Weisblum, B.; Gellman, S.H. Mimicry of host-defense peptides by unnatural oligomers: antimicrobial beta-peptides. J. Am. Chem. Soc. 2002, 124, 7324-7330.
120. Radzishevsky, I.S.; Rotem, S.; Bourdetsky, D.; Navon-Venezia, S.; Carmeli, Y.; Mor, A. Improved antimicrobial peptides based on acyl-lysine oligomers. Nat. Biotechnol. 2007, 25, 657-659.
121. Kruszewska, D.; Sahl, H.G.; Bierbaum, G.; Pag, U.; Hynes, S.O.; Ljungh, A. Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J. Antimicrob. Chemother. 2004, 54, 648-653.
122. Chatterjee, S.; Chatterjee, D.K.; Jani, R.H.; Blumbach, J.; Ganguli, B.N.; Klesel, N.; Limbert, M.; Seibert, G. Mersacidin, a new antibiotic from Bacillus. In vitro and in vivo antibacterial activity. J. Antibiot. (Tokyo) 1992, 45, 839-845.
123. Jevsevar, S.; Kunstelj, M.; Porekar, V.G. PEGylation of therapeutic proteins. Biotechnol. J. 2010, 5, 113-128.
124. Pasut, G.; Veronese, F.M. PEG conjugates in clinical development or use as anticancer agents: An overview. Adv. Drug Deliv. Rev. 2009, 61, 1177-1188.
125. Veronese, F.M.; Mero, A. The impact of PEGylation on biological therapies. BioDrugs 2008, 22, 315-329.
126. Imura, Y.; Nishida, M.; Ogawa, Y.; Takakura, Y.; Matsuzaki, K. Action mechanism of tachyplesin I and effects of PEGylation. Biochim. Biophys. Acta 2007, 1768, 1160-1169.
127. Imura, Y.; Nishida, M.; Matsuzaki, K. Action mechanism of PEGylated magainin 2 analogue peptide. Biochim. Biophys. Acta 2007, 1768, 2578-2585.
128. Zhang, G.; Han, B.; Lin, X.; Wu, X.; Yan, H. Modification of antimicrobial peptide with low molar mass poly(ethylene glycol). J. Biochem. 2008, 144, 781-788.
129. Isaacson, R.E. MBI-226. Micrologix/Fujisawa. Curr. Opin. Investig. Drugs 2003, 4, 999-1003.
130. Rubinchik, E.; Dugourd, D.; Algara, T.; Pasetka, C.; Friedland, H.D. Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models. Int. J. Antimicrob. Agents 2009, 34, 457-461.
131. Yeung, A.T.; Gellatly, S.L.; Hancock, R.E. Multifunctional cationic host defence peptides and their clinical applications. Cell. Mol. Life Sci. 2011, 68, 2161-2176.
132. Hancock, R.E.W.; Sahl, H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 2006, 24, 1551-1557.
133. Zaiou, M. Multifunctional antimicrobial peptides: Therapeutic targets in several human diseases. J. Mol. Med. 2007, 85, 317-329.
134. Zhang, L.; Falla, T.J. Antimicrobial peptides: Therapeutic potential. Expert Opin. Pharmacother. 2006, 7, 653-663.
135. Costerton, J.W.; Irvin, R.T.; Cheng, K.J. The bacterial glycocalyx in nature and disease. Ann. Rev. Microbiol. 1981, 35, 299-324.
136. Costerton, J. Introduction to biofilm. Int. J. Antimicrob. Agents 1999, 11, 217-221.
137. Hojo, K.; Nagaoka, S.; Ohshima, T.; Maeda, N. Bacterial interactions in dental biofilm development. J. Dent. Res. 2009, 88, 982-990.
138. Paju, S.; Scannapieco, F.A. Oral biofilms, periodontitis, and pulmonary infections. Oral Dis. 2007, 13, 508-512.
139. Palmer, J. Bacterial biofilms in chronic rhinosinusitis. Ann. Otol. Rhinol. Laryngol. Suppl. 2006, 196, 35-39.
140. Wagner, V.E. Iglewski, B.H. P. Aeruginosa Biofilms in CF Infection. Clin. Rev. Allergy Immunol. 2008, 35, 124-134.
141. Lau, G.W.; Hassett, D.J.; Britigan, B.E. Modulation of lung epithelial functions by Pseudomonas aeruginosa. Trends Microbiol. 2005, 13, 389-397.
142. Khardori, N.; Yassien, M. Biofilms in device-related infections. J. Ind. Microbiol. 1995, 15, 141-147.
143. Habash, M.; Reid, G. Microbial biofilms: their development and significance for medical device-related infections. J. Clin. Pharmacol. 1999, 39, 887-898.
144. Hoffman, L.R.; D'Argenio, D.A.; MacCoss, M.J.; Zhang, Z.; Jones, R.A.; Miller, S.I. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005, 436, 1171-1175.
145. Costerton, J.W.; Stewart, P.S.; Greenberg, E.P. Bacterial biofilms: a common cause of persistent infections. Science 1999, 284, 1318-1322.
146. Hall-Stoodley, L.; Stoodley, P. Evolving concepts in biofilm infections. Cell Microbiol. 2009, 11, 1034-1043.
147. Landini, P.; Antoniani, D.; Burgess, J.G.; Nijland, R. Molecular mechanisms of compounds affecting bacterial biofilm formation and dispersal. Appl. Microbiol. Biotechnol. 2010, 86, 813-823.
148. Horswill, A.R.; Stoodley, P.; Stewart, P.S.; Parsek, M.R. The effect of the chemical, biological, and physical environment on quorum sensing in structured microbial communities. Anal. Bioanal. Chem. 2007, 387, 371-380.
149. Spoering, A.L.; Gilmore, M.S. Quorum sensing and DNA release in bacterial biofilms. Curr. Opin. Microbiol. 2006, 9, 133-137.
150. Suntharalingam, P.; Cvitkovitch, D.G. Quorum sensing in streptococcal biofilm formation. Trends Microbiol. 2005, 13, 3-6.
151. Chen, G.; Swem, L.R.; Swem, D.L.; Stauff, D.L.; O'Loughlin, C.T.; Jeffrey, P.D.; Bassler, B.L.; Hughson, F.M. A strategy for antagonizing quorum sensing. Mol Cell. 2011, 42, 199-209.
152. Waters, C.M.; Bassler, B.L. Quorum sensing: Cell-to-cell communication in bacteria. Annu. Rev. Cell Dev. Biol. 2005, 21, 319-346.
153. Sutherland, I. Biofilm exopolysaccharides: A strong and sticky framework. Microbiology 2001, 147, 3-9.
154. Moreau-Marquis, S.; Stanton, B.A.; O'Toole, G.A. Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. Pulm. Pharmacol. Ther. 2008, 21, 595-599.
155. Overhage, J.; Campisano, A.; Bains, M.; Torfs, E.C.; Rehm, B.H.; Hancock, R.E. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect. Immun. 2008, 76, 4176-4182.
156. Hell, E.; Giske, C.G.; Nelson, A.; Römling, U.; Marchini, G. Human cathelicidin peptide LL37 inhibits both attachment capability and biofilm formation of Staphylococcus epidermidis. Lett. Appl. Microbiol. 2010, 50, 211-215.
157. Amer, L.S.; Bishop, B.M.; van Hoek, M.L. Antimicrobial and antibiofilm activity of cathelicidins and short, synthetic peptides against Francisella. Biochem. Biophys. Res. Commun. 2010, 396, 246-251.
158. Porat, Y.; Marynka, K.; Tam, A.; Steinberg, D.; Mor, A. Acyl-substituted dermaseptin S4 derivatives with improved bactericidal properties, including on oral microflora. Antimicrob. Agents Chemother. 2005, 50, 4153-4160.
159. Laverty, G.; McLaughlin, M.; Shaw, C.; Gorman, S.P.; Gilmore, B.F. Antimicrobial activity of short, synthetic cationic lipopeptides. Chem. Biol. Drug Des. 2010, 75, 563-569.
160. Roveta, S.; Marchese, A.; Schito, G.C. Activity of daptomycin on biofilms produced on a plastic support by Staphylococcus spp. Int. J. Antimicrob. Agents 2008, 31, 321-328.
161. Høiby, N.; Bjarnsholt, T.; Givskov, M.; Molin, S.; Ciofu, O. Antibiotic resistance of bacterial biofilms. Int. J. Antimicrob. Agents 2010, 35, 322-332.
162. Yoshinari, M.; Kato, T.; Matsuzaka, K.; Hayakawa, T.; Shiba, K. Prevention of biofilm formation on titanium surfaces modified with conjugated molecules comprised of antimicrobial and titanium-binding peptides. Biofouling 2010, 26, 103-110.
163. Willcox, M.D.; Hume, E.B.; Aliwarga, Y.; Kumar, N.; Cole, N. A novel cationic-peptide coating for the prevention of microbial colonization on contact lenses. J. Appl. Microbiol. 2008, 105, 1817-1825.
164. Cole, N.; Hume, E.B.; Vijay, A.K.; Sankaridurg, P.; Kumar, N.; Willcox, M.D. In vivo performance of melimine as an antimicrobial coating for contact lenses in models of CLARE and CLPU. Invest. Ophthalmol. Vis. Sci. 2010, 51, 390-395.
165. Cirioni, O.; Giacometti, A.; Ghiselli, R.; Kamysz, W.; Orlando, F.; Mocchegiani, F.; Silvestri, C.; Licci, A.; Chiodi, L.; Lukasiak, J.; Saba, V.; Scalise, G. Citropin 1.1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection. Peptides 2006, 27, 1210-1216.
166. Marsh, P.D. Dental plaque: Biological significance of a biofilm and community life-style. J. Clin. Periodontol. 2005, 32, 7-15.
167. Rudney, J.D. Saliva and dental plaque. Adv. Dent. Res. 2000, 14, 29-39.
168. Marsh, P.D.; Bradshaw, D.J. Dental plaque as a biofilm. J. Ind. Microbiol. 1995, 15, 169-175.
169. Sissons, C.H.; Anderson, S.A.; Wong, L.; Coleman, M.J.; White, D.C. Microbiota of plaque microcosm biofilms: Effect of three times daily sucrose pulses in different simulated oral environments. Caries Res. 2007, 41, 413-422.
170. Filoche, S.; Wong, L.; Sissons, C.H. Oral biofilms: Emerging concepts in microbial ecology. J. Dent. Res. 2010, 89, 8-18.
171. Leung, K.P.; Abercrombie, J.J.; Campbell, T.M.; Gilmore, K.D.; Bell, C.A.; Faraj, J.A.; DeLuca, P.P. Antimicrobial peptides for plaque control. Adv. Dent. Res. 2009, 21, 57-62.
172. Eberhard, J.; Pietschmann, R.; Falk, W.; Jepsen, S.; Dommisch, H. The immune response of oral epithelial cells induced by single-species and complex naturally formed biofilms. Oral Microbiol. Immunol. 2009, 24, 325-330.
173. Lobos, O.; Padilla, A.; Padilla, C. In vitro antimicrobial effect of bacteriocin PsVP-10 in combination with chlorhexidine and triclosan against Streptococcus mutans and Streptococcus sobrinus strains. Arch. Oral Biol. 2009, 54, 230-234.
174. Wakabayashi, H.; Yamauchi, K.; Kobayashi, T.; Yaeshima, T.; Iwatsuki, K.; Yoshie, H. Inhibitory effects of lactoferrin on growth and biofilm formation of Porphyromonas gingivalis and Prevotella intermedia. Antimicrob. Agents Chemother. 2009, 53, 3308-3316.
175. Arslan, S.Y.; Leung, K.P.; Wu, C.D. The effect of lactoferrin on oral bacterial attachment. Oral Microbiol. Immunol. 2009, 24, 411-416.
176. Wakabayashi, H.; Kondo, I.; Kobayashi, T.; Yamauchi, K.; Toida, T.; Iwatsuki, K.; Yoshie, H. Periodontitis, periodontopathic bacteria and lactoferrin. Biometals 2010, 23, 419-424.
177. Darouiche, R.O.; Mansouri, M.D.; Gawande, P.V.; Madhyastha, S. Antimicrobial and antibiofilm efficacy of triclosan and DispersinB combination. J. Antimicrob. Chemother. 2009, 64, 88-93.
178. Kaplan, J.B. Therapeutic potential of biofilm-dispersing enzymes. Int. J. Artif. Organs 2009, 32, 545-554.
179. Izano, E.A.; Amarante, M.A.; Kher, W.B.; Kaplan, J.B. Differential roles of poly-N-acetylglucosamine surface polysaccharide and extracellular DNA in Staphylococcus aureus and Staphylococcus epidermidis biofilms. Appl. Environ. Microbiol. 2008, 74, 470-476.